Published in Gene Therapy Weekly, February 17th, 1997
The composition of matter patent on the gene mutation, which is believed to be associated with an individual's risk for salt-dependent hypertension, was issued to the University of Utah, and is licensed exclusively to Myriad Genetics, Inc. for therapeutic applications, and also licensed to Myriad for diagnostic applications.
The patent solidifies Myriad's proprietary position as it proceeds toward the commercialization of AGTanalysis. AGTanalysis is the company's genetic test for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.